secwatch.observer — SEC 8-K summary
======================================

Issuer:     Can B Corp (NASC)
CIK:        0001509957
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001493152-24-009065
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Can B Corp. subsidiary Nascent Pharma acquires two cannabis liquid formulation patents valued at $122M
--------------------------------------------------------------------------------

- Nascent Pharma, 67% owned by Can B, acquired US patents 9,730,911 and 10,555,928 covering liquid cannabis formulations including beverages, tinctures, vape pens, and capsules.
- Independent 2020 valuation set patent value at $122M, applying a 90% discount on projected income streams through August 2034.
- Nascent agreed to pay prior patent owner's creditors 5% of Can B's share of Nascent revenues until aggregate $10M paid.
- Consulting agreement with inventor entitles consultant to 50% of distributions Can B receives from Nascent.
- Can B warns no assurance patents will generate revenue or achieve the $122M valuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509957/000149315224009065/0001493152-24-009065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509957/000149315224009065/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer